期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 17, 期 5, 页码 615-618出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.5.615
关键词
atherosclerosis; CGS23425; coronary heart disease; GC-1; KB-141; KB-2115; thyromimetics
Background: Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited. Objective: One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of recent developments. Methods: The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome). Conclusion: The published data provide proof of concept/mechanism, opening the way to larger studies in a wider range of subjects and in combination with statins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据